You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction
SBC: COGNITION THERAPEUTICS, INC. Topic: NIAAbstractProject Summary Cognition Therapeutics IncsCogrxmission is to develop effective therapeutics for Alzheimer s diseaseADOligomers of the brain protein Amyloid betaA Oshave been identified as toxic components that are involved with disease progressionCognition has identified a subset of sigmareceptor binding modulators that displaces A Os from synaptic receptor sites and clears them into the ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Automated Object Contouring Methods and Software for Radiotherapy Planning
SBC: Quantitative Radiology Solutions LLC Topic: 102Abstract In 2015, 1,658,370 new cancer cases are estimated to occur in the US, where nearly two-thirds will have radiation therapy (RT). Given that there are over 2,300 RT centers in the US, and current systems for contouring organs at risk (OARs) rely mostly on manual methods, there is a strong commercial opportunity for producing a software system that can contour OARs in medical images at a hig ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Measuring Bladder Permeability with MRI Using a Novel Contrast Agent Formulation
SBC: Lipella Pharmaceuticals Inc. Topic: 300ABSTRACT This Phase II SBIR proposal leverages the progress made in Phase I on the development of a novel contrast mixture enhanced Tweighted MRI technique as a safesensitiveand objective diagnostic test for the increased permeability in the luminal surface of the urinary bladder in Interstitial Cystitis Bladder Pain SyndromeIC BPSpatientsThe purpose of having such a test is ultimately to allow cl ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples
SBC: CIRCA BIOSCIENCE LLC Topic: 102Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIAIDThe ultimate goal of this Phase I application is to develop novel small moleculebroad spectrum therapeutics against viral infections caused by filoviruses that depend on the PPxY L domain motif for virus egress and spread of infectionEbolaEBOVand MarburgMARVviruses are highly pathogenic and classified as Category Ahigh priority bioterror pathogensAs there are no commercially available therapeutic ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate
SBC: NeuroKine Therapeutics, LLC Topic: NIAABSTRACT Alzheimer s diseaseADand related dementias are increasing rapidly yetremarkablythere are no approved disease modifying drugsVirtually all trials targeting amyloid related pathways have failed over the lastyearsRegrettablyfew alternative targets or pathways have been exploredThereforethere is an urgent need to explore alternative pathways as monotherapies or as constituents of a multi drug ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Product for sensitive imaging of cells in vivo
SBC: CELSENSE, INC. Topic: NIBIBThis project aims to develop and commercialize a novel and highly sensitive MRI probe technology for the cell therapy tools marketThis project will transfer technology invented in the academic lab of DrAhrens at UCSDto CelsenseIncan established company that offers imaging agents for visualizing the trafficking of cell therapies and inflammation in the body using magnetic resonance imagingMRIOveral ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil
SBC: AcePre, LLC Topic: NCCIHPROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health